Skip to main content


Pulsed Field Ablation System

*Caution: Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale.



The objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug-resistant, symptomatic-persistent atrial fibrillation (PersAF).


Farapulse posterior wall animation

Feasibility data

Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation
  • In PersAFOne, persistent AF patients underwent PVI and LA posterior wall ablation (LAPW) using a basket and flower PFA catheter. 
  • In 25 patients, acute PVI was achieved in 100% of PVs; in 24 patients, acute ablation was successful in 100% of LAPWs with PFA alone. 
  • PV remapping, performed in 22 patients at an average of 82 days, demonstrated durable isolation in 96% of PVs (86% of patients), and 100% of LAPWs (21 of 21). 
  • The 1-year Kaplan-Meier estimate for freedom from any atrial arrhythmia was 92.5 +/- 5.4%.

Find a site

Please refer to the active site list for contact information for a study physician near you.
Farapulse clinical compendium